GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

GSK GSK1.94%increase; green up pointing triangle cut its full ... The British pharmaceutical giant said vaccine demand was ...

Have a nice week! It’s hard to know exactly what change in Washington will mean for the health care industry starting next ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Phenylephrine:CVS pulls cold medicines with the ingredient Companies such as Procter & Gamble and GSK were among several accused in ... or remove such drugs from the market. The Consumer Healthcare ...

This might be lower than the stock's five-year average levels of 4.65%, but it's still higher than the healthcare sector's average of 1.47%. The big picture for the GSK story remains unchanged.

The collaboration agreement was signed by Dr. Ramadan Al Blooshi, Advisor to the Director General and Acting Director of the ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Health Canada has approved Moderna’s mRNA vaccine to protect ... in Canada to protect seniors against severe illness caused ...